USANA Health Sciences Inc (USNA) FinancialsUSNAUSANA Health Sciences Inc

USANA Health Sciences Inc (USNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is USANA® Nutritionals, accounting for 86.0% of total sales, equivalent to $215.19M. Other significant revenue streams include USANA Foods and Personal care and Skincare. Understanding this composition is critical for investors evaluating how USNA navigates market cycles within the Food Processing industry.

Evaluating the bottom line, USANA Health Sciences Inc maintains a gross margin of 78.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.09%, while the net margin is -12.52%. These profitability ratios, combined with a Return on Equity (ROE) of -4.19%, provide a clear picture of how effectively USNA converts its operational activities into shareholder value.

In the context of the broader market, USNA competes directly with industry leaders such as NAGE and NATR. With a market capitalization of $247.03M, it holds a significant position in the sector. When comparing efficiency, USNA's gross margin of 78.35% stands against NAGE's 64.84% and NATR's 73.66%. Such benchmarking helps identify whether USANA Health Sciences Inc is trading at a premium or discount relative to its financial performance.

USANA's financial performance has been troubling, with a 5.3% decline in Q2 revenue year-over-year, missing analyst expectations. The gross margin has also decreased to 76.25% in Q1 2026, down from 80.39% in Q3 2024, indicating challenges in maintaining profitability.